
From Dog Ticks to Human Vaccines: A Growing Push to Prevent Lyme Disease
Lyme disease cases are rising as ticks expand due to climate change, and there are currently no licensed vaccines for people, though several are advancing. Pfizer/Valneva's four-dose PF-07307405 vaccine showed over 70% efficacy in a large phase 3 trial; Moderna is testing two Lyme vaccines in phase 2; Yale is exploring a tick-saliva–targeting approach; and Tonix's TNX-4800 antibody injections are in early trials, with Tarsus pursuing an oral pill. In dogs, tick protection is common, while preventive strategies for humans emphasize avoiding tall grass, protective clothing, and thorough tick checks. A prior human vaccine, LYMErix, disappeared in 2002 due to safety concerns and low demand.













